Elizabeth Drew
Family Medicine · Doylestown, PANPI 1902833718
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,845 of the $97,608 with a category attached, or 85.9%. Braeburn Inc. accounts for 84.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $48,857 and has fallen 54.6% since, to $22,199 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $570.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braeburn Inc.$82K
- Alkermes, Inc.$11K
- Indivior Inc.$4K
- Orexo US, Inc.$85
- Bausch Health US, LLC$59
- Gilead$43
- plus $32 from 2 others
What the payments were for
- Speaking & faculty fees$83,84586%
- Travel & lodging$10,02110%
- Food & beverage$3,7174%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braeburn Inc. | 114 | $81,996 |
| Alkermes, Inc. | 26 | $11,309 |
| Indivior Inc. | 18 | $4,085 |
| Orexo US, Inc. | 5 | $85 |
| Bausch Health US, LLC | 3 | $59 |
| Gilead | 3 | $43 |
| Kaleo, Inc. | 1 | $21 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,608 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 57 | $46,583 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 195 | $22,943 |
| Trazodone Hcl | 14 | $144 |
| Pregabalin | 27 | $128 |
| Clonidine Hcl | 16 | $70 |
| Clonazepam | 11 | $28 |
| Tramadol Hcl | 13 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $4,085 | $46,58357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Doylestown
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.